Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Beijing Tong Ren Tang Chinese Medicine Co Ltd

Beijing Tong Ren Tang Chinese Medicine Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)8.32
  • Today's Change0.19 / 2.34%
  • Shares traded1.94m
  • 1 Year change-29.97%
  • Beta0.7212
Data delayed at least 15 minutes, as of Nov 01 2024 08:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Beijing Tong Ren Tang Chinese Medicine Company Limited is a company mainly engaged in the manufacturing and sale of Chinese medicine. Along with subsidiaries, it operates its business through three segments. The Hong Kong segment engages in the sale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments through retail outlets as well as wholesale of Chinese medicine products in Hong Kong. It is also involved in the royalty fee income from overseas entities using the brand of Tong Ren Tang. The Mainland China segment engages in the wholesale of healthcare products in Mainland China and the sole distribution of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd. to customers outside Mainland China. The Overseas segment engages in the retail and wholesale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments in other overseas countries.

  • Revenue in HKD (TTM)1.38bn
  • Net income in HKD494.14m
  • Incorporated2004
  • Employees779.00
  • Location
    Beijing Tong Ren Tang Chinese Medicine Co LtdRoom 1405-1409, Office Tower, Hong KongHKG
  • Phone+852 36575819
  • Fax+852 28817606
  • Websitehttps://cm.tongrentang.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cutia Therapeutics217.21m-572.76m3.96bn360.00--3.04--18.23-1.88-1.880.71364.260.12062.316.93728,907.80-31.81---35.82--50.33---263.68--4.82--0.1818--1,110.83---253.30------
Jiangsu Recbio Technology Co Ltd0.00-599.19m4.12bn507.00--4.48-----1.25-1.250.001.910.00----0.00-25.33---32.84----------0.9619--0.4548------20.86------
Ocumension Therapeutics338.94m-352.52m4.58bn477.00--1.28--13.53-0.5379-0.53790.5174.360.1032.402.48763,383.40-10.71-38.78-11.55-41.4758.2962.30-104.01-975.825.00--0.0055--54.99--5.68--319.66--
Beijing Luzhu Biotechnology Co Ltd0.00-305.78m4.87bn148.00--4.76-----1.51-1.510.005.090.00----0.00-23.80---25.44----------5.91--0.0296------65.62------
Shandong Boan Biotechnology Co Ltd786.30m67.51m4.88bn777.0068.723.0534.086.210.13260.13261.542.990.30691.102.60967,157.302.63--3.43--74.10--8.59--1.034.010.3369--19.80--64.02------
Tong Ren Tang Technologies Co Ltd7.51bn710.87m6.54bn4.01k9.210.84444.600.87120.5550.5555.876.050.50260.98815.221,831,768.007.427.6811.6912.3240.9743.5014.7616.112.30--0.196839.9413.046.011.25-2.73-22.26-0.0089
Sihuan Pharmaceutical Holdings Group Ltd1.92bn-41.29m6.80bn2.65k--1.41--3.55-0.0045-0.00450.20650.51820.15060.8943.90667,311.90-1.77-6.85-2.68-9.1065.9175.81-11.78-36.231.50--0.181---14.70-8.6097.23--0.9325--
Beijing Tong Ren Tang Chinese Medicine1.38bn494.14m6.81bn779.0013.771.7911.014.940.59030.59031.644.550.32840.35543.621,725,133.0012.7216.7114.0918.7572.0669.8838.7240.729.55--0.032768.87-11.910.1459-16.33-1.43-16.307.49
Consun Pharmaceutical Group Ltd2.99bn913.63m6.99bn3.18k7.301.736.992.341.131.133.714.790.52092.0012.89956,784.4015.9712.0423.2419.2574.2274.5530.6624.892.80--0.114440.8410.717.0314.8811.01-22.9318.43
China Shineway Pharmaceutical Group Ltd4.59bn1.21bn7.61bn3.23k5.760.94945.461.661.601.606.089.690.44761.285.261,336,654.0011.768.0315.479.7775.2174.5526.2717.873.14--0.045736.2914.3211.9434.1413.890.639612.88
Yichang Hec Changjiang Pharmactcl Co Ltd6.05bn1.80bn7.76bn4.89k4.310.823.711.282.052.056.8810.760.42722.503.741,310,494.0011.698.0317.2711.8178.9079.9727.3720.801.9350.790.212615.8168.0820.182,501.2416.15-11.50--
AIM Vaccine Co Ltd1.29bn-1.30bn9.10bn1.56k--2.38--7.03-1.07-1.071.073.160.14620.63251.10796,494.10-22.69---37.16--72.34---155.22--0.6836-6.610.3437---6.06---307.07------
Data as of Nov 01 2024. Currency figures normalised to Beijing Tong Ren Tang Chinese Medicine Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

6.99%Per cent of shares held by top holders
HolderShares% Held
Value Partners Ltd.as of 30 Jun 202422.96m2.74%
E Fund Management Co., Ltd.as of 30 Jun 202413.01m1.55%
The Vanguard Group, Inc.as of 02 Oct 20248.36m1.00%
Dimensional Fund Advisors LPas of 03 Oct 20244.19m0.50%
BlackRock Fund Advisorsas of 03 Oct 20243.90m0.47%
China Merchants Fund Management Co., Ltd.as of 30 Jun 20242.34m0.28%
Bosera Asset Management Co., Ltd.as of 30 Jun 20241.63m0.19%
BlackRock Advisors (UK) Ltd.as of 03 Oct 2024771.34k0.09%
American Century Investment Management, Inc.as of 03 Oct 2024705.00k0.08%
AllianceBernstein Ltd.as of 30 Jun 2024690.00k0.08%
More ▼
Data from 30 Jun 2024 - 23 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.